---
document_datetime: 2023-12-21 16:29:36
document_pages: 6
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/ivabradine-anpharm-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: ivabradine-anpharm-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 3.9497838
conversion_datetime: 2025-12-28 08:32:00.32496
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Ivabradine Anpharm

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                    | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| WS/2569              | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing | 14/12/2023                          | n/a                                         |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                    | authorisation, including the RMP - Other variation                                                                                                                                                                                                     |            |            |                                                                                                                                                                             |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/1799/ 202304 | Periodic Safety Update EU Single assessment - ivabradine                                                                                                                                                                                               | 30/11/2023 | n/a        | PRAC Recommendation - maintenance                                                                                                                                           |
| IG/1674            | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                    | 06/11/2023 | n/a        |                                                                                                                                                                             |
| IG/1670            | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                       | 12/10/2023 | n/a        |                                                                                                                                                                             |
| IAIN/0017/G        | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site | 27/01/2023 | n/a        |                                                                                                                                                                             |
| N/0016             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                       | 20/10/2021 |            |                                                                                                                                                                             |
| PSUSA/1799/ 202004 | Periodic Safety Update EU Single assessment - ivabradine                                                                                                                                                                                               | 14/01/2021 | n/a        | PRAC Recommendation - maintenance                                                                                                                                           |
| R/0014             | Renewal of the marketing authorisation.                                                                                                                                                                                                                | 26/03/2020 | 20/05/2020 | Based on the review of data on quality, safety and efficacy, including all variations introduced since the marketing authorisation was granted, the benefit-risk balance of |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                                                                                                                                                   |            |            |          | Ivabradine Anpharm in its approved indication(s) (please refer to the Summary of Product Characteristics) remains favourable and therefore the renewal of the marketing authorisation is recommended, subject to the conditions as detailed in Annex II. The renewal is recommended to be granted with unlimited validity.              |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/1641 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) | 11/07/2019 | n/a        |          |                                                                                                                                                                                                                                                                                                                                         |
| N/0012  | Notification Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                     | 14/06/2019 | 20/05/2020 | PL       |                                                                                                                                                                                                                                                                                                                                         |
| IA/0011 | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                     | 12/04/2019 | n/a        |          |                                                                                                                                                                                                                                                                                                                                         |
| SW/0010 |                                                                                                                                                                                                                                                                                                                                                                   | 18/10/2018 | 07/01/2019 | Annex II | The results of this DUS study showed an increase in adherence to the SmPC guidelines in the post-RMM period compared to the pre-RMM period. This increase in adherence was measured for all the four criteria under study. Therefore, in view of available data regarding the PASS final study report, the PRAC considered that changes |

<div style=\"page-break-after: always\"></div>

|                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |            |            |                        | to the conditions of the marketing authorisation were warranted.   |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|--------------------------------------------------------------------|
| PSUSA/1799/ 201804 | Periodic Safety Update EU Single assessment - ivabradine                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 29/11/2018 | n/a        |                        | PRAC Recommendation - maintenance                                  |
| WS/1352/G          | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. A.7 - Administrative change - Deletion of manufacturing sites B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) | 03/05/2018 | n/a        |                        |                                                                    |
| WS/1180            | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of the RMP with current information on epidemiology, post-authorisation exposure and post                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 11/01/2018 | 07/01/2019 | SmPC, Labelling and PL |                                                                    |

<div style=\"page-break-after: always\"></div>

|                    | authorisation studies status including the due date of the final study report for Ivabradine Drug Utilisation Study. The Annex II has been updated accordingly. In addition the MAH took the opportunity to align the PI with the latest QRD template 10.0 and introduce minor updates to the ADR terms. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                          |            |     |                                   |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| PSUSA/1799/ 201704 | Periodic Safety Update EU Single assessment - ivabradine                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 30/11/2017 | n/a | PRAC Recommendation - maintenance |
| PSUSA/1799/ 201604 | Periodic Safety Update EU Single assessment - ivabradine                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 01/12/2016 | n/a | PRAC Recommendation - maintenance |
| WS/0932/G          | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new | 07/07/2016 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

|           | corresponding test method B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                           |            |            |                                  |                                                                                                                                                                            |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0004 | C.I.11.a - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of wording agreed by the competent authority                                                                                                                                                                                                                                                                                                                     | 06/07/2016 | 08/05/2017 | Annex II                         |                                                                                                                                                                            |
| WS/0914   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of sections 4.4 and 5.1 of the SmPC in order to update the information on retinal safety. In addition, the Marketing authorisation holder (MAH) took the opportunity to bring the PI in line with the latest QRD template version 9.1. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 28/04/2016 | 08/05/2017 | SmPC, Annex II, Labelling and PL | In this variation the MAH updated the Product information to indicate that to date there is no evidence of a toxic effect of long-term ivabradine treatment on the retina. |